
Infliximab could restore disease response after drug holiday
Subcutaneous (SC) infliximab could restore and maintain disease response in most Crohn’s disease (CD) and ulcerative colitis (UC) patients, data shows. Results announced by biopharmaceutical company Celltrion demonstrated that initiating subcutaneous (SC) infliximab after a treatment interruption, following intravenous (IV) infliximab induction, helps patients with Crohn’s disease (CD) and ulcerative colitis… Read More















